Influence of SPINK1 Gene Polymorphism on Efficacy of Ulinastatin in Treatment of Acute Pancreatitis
10.3969/j.issn.1008-7125.2019.06.006
- Author:
Hong LI
1
Author Information
1. Department of Spleen, Stomach and Liver Diseases, Baoji Hospital of Traditional Chinese Medicine
- Publication Type:Journal Article
- Keywords:
Acute Pancreatitis;
Gene;
Polymorphism;
Single Nucleotide;
SPINK1;
Therapy;
Ulinastatin
- From:
Chinese Journal of Gastroenterology
2019;24(6):345-349
- CountryChina
- Language:Chinese
-
Abstract:
Background: Ulinastatin is an important drug for the treatment of acute pancreatitis (AP). However, there are some differences in the efficacy of ulinastatin among different patients. Aims: To explore influence of SPINK1 gene polymorphism on the efficacy of ulinastatin in treatment of AP. Methods: A total of 572 patients with AP from January 2005 to December 2015 at Baoji Hospital of Traditional Chinese Medicine were enrolled. Ulinastatin 100 000 U was given intravenously. Mutation of SPINK1 gene was detected by PCR. The levels of TNF-α, IL-2, IL-8, IL-10 and blood, urine amylase were determined by ELISA. The efficacy of ulinastatin was evaluated. Results: Rate of c.101A>G mutation in AP patients was significantly higher than that in the control group (P<0.05). c.200G>A mutation resulted in a significant decrease of SPINK1 mRNA expression (P<0.05). The remission rate of jaundice was significantly lower in AP patients with c.36G>C and c.200G>A mutations than in wild type (P<0.05). The levels of TNF-α, IL-8 in c.200G>A mutation were significantly decreased than those in wild type (P<0.05). The decrease trend of positive amylase in blood and urine was weaker in AP patients with c.200G>A mutation (P<0.05). The efficacy rate in AP patients with c.36G>C and c.200G>A mutations was significantly lower than that in wild type (P<0.05). Conclusions: The rate of c.101A>G mutation in patients with AP is higher than that in general population. Mutations of c. 36G>C and c.200G>A could influence the efficacy of ulinastatin for the treatment of AP.
